Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations
Zoetis (NYSE:ZTS) reported Q2 CY2026 sales of $2.47 billion, flat year on year, and below market expectations. The company’s full-year revenue guidance midpoint of $9.22 billion was 5.4% below analysts’ estimates. Non-GAAP adjusted EPS was $1.87, up from $1.76, about in line with consensus.
How this was made
The 30-second read
Why it matters
The key tradable update is the full-year revenue guidance midpoint coming in 5.4% below analysts’ estimates, alongside a Q2 revenue miss and flat YoY sales. Adjusted EPS was near consensus and slightly above, which may reduce downside momentum but does not negate the revenue-guidance reset.
Market read
A revenue and guidance miss is likely to drive estimate revisions and near-term sentiment, even as EPS performance appears steadier.
What to watch
The article lacks segment/product drivers for the revenue miss, so traders may overreact without knowing whether the shortfall is temporary (mix, timing) versus structural.
Background
Zoetis is a pure-play animal health company; the article frames its Q2 CY2026 results versus Wall Street expectations and discusses longer-term growth and profitability trends.
Ticker impact
Zoetis reported Q2 CY2026 sales of $2.47B, flat YoY, and guided full-year revenue to $9.22B midpoint, 5.4% below estimates.
Bias toward downside or volatility in the next few sessions as traders reprice FY revenue expectations; EPS strength may limit the selloff.
The article provides specific Q2 revenue and full-year revenue guidance vs analyst estimates, which are direct inputs to valuation and forward estimates. It also notes adjusted EPS was slightly above consensus, which can partially offset the revenue-driven negative read-through.
Market effects
Animal health peers may see read-across on demand durability and pricing power if Zoetis’ revenue growth decelerates.
Primarily US large-cap healthcare sentiment; limited direct regional spillover implied.
Global animal health demand expectations may be modestly tempered by the guidance shortfall.
Counterpoint
EPS slightly beat and operating margin strength plus buyback-driven EPS growth could keep the market focused on earnings quality rather than revenue softness.
Key entities
- companyZoetis
Animal health company reporting Q2 CY2026 results and full-year revenue guidance.
- market participantsWall Street analysts
Consensus estimates referenced for both Q2 and full-year revenue comparisons.
